Physician profile
Amanda L Mabus
NPI 1609181056
$1,526.81
in general payments reported to CMS, 2019-2025
18 companies · $1,180 in 2025
The $1,180 reported for 2025 was more than what 86% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $83.43 · 2022: $18.21 · 2023: $65.88 · 2024: $179 · 2025: $1,180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,331 · Education: $94.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,330.53 |
| Education | $94.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $521.71 | 2024-2025 | |
| Madrigal Pharmaceuticals | $304.70 | 2025 | Rezdiffra |
| Janssen Biotech, INC. | $222.45 | 2025 | Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $80.07 | 2024-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $73.85 | 2024-2025 | Xifaxan |
| Insulet Corporation | $70.60 | 2021 | |
| Abbott Laboratories | $40.56 | 2023-2024 | Freestyle Libre 2 |
| Medtronic, INC. | $29.99 | 2023 | Minimed 780g |
| Genzyme Corporation | $22.54 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $22.40 | 2025 | Dupixent |
| Aimmune Therapeutics, INC. | $20.68 | 2025 | Zenpep |
| Ipsen Biopharmaceuticals, INC | $20.27 | 2025 | Iqirvo |
| Tandem Diabetes Care, INC. | $18.21 | 2022 | |
| Intercept Pharmaceuticals, INC. | $17.74 | 2025 | |
| Phathom Pharmaceuticals, INC. | $17.56 | 2025 | Voquezna |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.38 | 2023 | |
| Ardelyx, INC. | $15.27 | 2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $12.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Mabus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.